Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totaling 146,851 shares, a drop of 68.4% from the September 15th total of 464,825 shares. Based on an average daily trading volume, of 403,096 shares, the short-interest ratio is currently 0.4 days. Currently, 1.1% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
BFRI has been the topic of a number of research reports. Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen cut Biofrontera from a “buy” rating to a “hold” rating in a research note on Sunday, September 20th. Finally, Zacks Research raised Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Biofrontera presently has an average rating of “Hold”.
Get Our Latest Research Report on BFRI
Biofrontera Trading Down 3.6%
Biofrontera (NASDAQ:BFRI – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $9.50 million. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%. As a group, sell-side analysts expect that Biofrontera will post -0.60 EPS for the current year.
About Biofrontera
Biofrontera Inc (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing dermatology products in the United States. The company’s activities center on treatments for actinic keratosis, a common precancerous skin condition caused by sun exposure.
Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription treatment used in combination with photodynamic therapy to treat mild-to-moderate actinic keratoses on the face and scalp.
Further Reading
- Five stocks we like better than Biofrontera
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
- Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
